LILRB1 antibody (PE)
-
- Target See all LILRB1 Antibodies
- LILRB1 (Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 1 (LILRB1))
-
Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This LILRB1 antibody is conjugated to PE
-
Application
- Flow Cytometry (FACS)
- Specificity
- The mouse monoclonal antibody GHI/75 recognizes an extracellular epitope of CD85j / ILT2, an 110-120 kDa membrane glycoprotein expressed strongly on plasma cells, moderately on circulating B cells, and weakly on monocytes. It is also expressed on T cell and NK cell subsets (variable, individual).
- Cross-Reactivity (Details)
- Human
- Purification
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- Immunogen
- Hairy cell leukaemia cells
- Clone
- GHI-75
- Isotype
- IgG2b kappa
- Top Product
- Discover our top product LILRB1 Primary Antibody
-
-
- Application Notes
- Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 106 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
- Comment
-
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- Restrictions
- For Research Use only
-
- Reconstitution
- No reconstitution is necessary.
- Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handling Advice
-
Do not freeze.
Avoid prolonged exposure to light. - Storage
- 4 °C
- Storage Comment
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells." in: Neoplasia (New York, N.Y.), Vol. 13, Issue 9, pp. 822-30, (2011) (PubMed).
: "HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition." in: International immunology, Vol. 13, Issue 2, pp. 193-201, (2001) (PubMed).
: "Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily." in: Journal of leukocyte biology, Vol. 65, Issue 6, pp. 841-5, (1999) (PubMed).
: "
-
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells." in: Neoplasia (New York, N.Y.), Vol. 13, Issue 9, pp. 822-30, (2011) (PubMed).
-
- Target
- LILRB1 (Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 1 (LILRB1))
- Alternative Name
- CD85j / ILT2 (LILRB1 Products)
- Background
- Leukocyte immunoglobulin like receptor B1,CD85j, also known as ILT-2 (Ig-like transcript 2), LIR-1 (leukocyte Ig-like receptor 1), or LILRB1 (leukocyte Ig-like receptor B1), is a member of Ig superfamily transmembrane glycoproteins named CD85. The CD85j protein is expressed on several types of immune cells (plasma cells, B cells, monocytes, T and NK cell subsets) where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity.,ILT2, LIR1, MIR7, PIRB, ILT-2
- Gene ID
- 10859
- UniProt
- Q8NHL6
- Pathways
- Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response
-